BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 33802841)

  • 1. FGF/FGFR Signaling in Hepatocellular Carcinoma: From Carcinogenesis to Recent Therapeutic Intervention.
    Wang Y; Liu D; Zhang T; Xia L
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33802841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets.
    Wang H; Yang J; Zhang K; Liu J; Li Y; Su W; Song N
    Front Pharmacol; 2021; 12():650388. PubMed ID: 33935756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling.
    Agrawal S; Maity S; AlRaawi Z; Al-Ameer M; Kumar TKS
    Curr Drug Targets; 2021; 22(2):214-240. PubMed ID: 33045958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma.
    Tamburello M; Altieri B; Sbiera I; Sigala S; Berruti A; Fassnacht M; Sbiera S
    Endocrine; 2022 Sep; 77(3):411-418. PubMed ID: 35583844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma.
    Le TBU; Vu TC; Ho RZW; Prawira A; Wang L; Goh BC; Huynh H
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33321903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives.
    Santolla MF; Maggiolini M
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33081025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR a promising druggable target in cancer: Molecular biology and new drugs.
    Porta R; Borea R; Coelho A; Khan S; Araújo A; Reclusa P; Franchina T; Van Der Steen N; Van Dam P; Ferri J; Sirera R; Naing A; Hong D; Rolfo C
    Crit Rev Oncol Hematol; 2017 May; 113():256-267. PubMed ID: 28427515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast Growth Factor Receptor Signaling in Skin Cancers.
    Czyz M
    Cells; 2019 Jun; 8(6):. PubMed ID: 31167513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma.
    Cheng AL; Shen YC; Zhu AX
    Oncology; 2011; 81(5-6):372-80. PubMed ID: 22269894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications.
    Dianat-Moghadam H; Teimoori-Toolabi L
    Curr Drug Targets; 2019; 20(8):852-870. PubMed ID: 30648505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future applications of FGF/FGFR inhibitors in cancer.
    Ghedini GC; Ronca R; Presta M; Giacomini A
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):861-872. PubMed ID: 29936878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
    Ronca R; Giacomini A; Rusnati M; Presta M
    Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma.
    Coleman SJ; Grose RP; Kocher HM
    J Hepatocell Carcinoma; 2014; 1():43-54. PubMed ID: 27508175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression.
    Li Q; Alsaidan OA; Ma Y; Kim S; Liu J; Albers T; Liu K; Beharry Z; Zhao S; Wang F; Lebedyeva I; Cai H
    J Biol Chem; 2018 Apr; 293(17):6434-6448. PubMed ID: 29540482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis.
    Zhang J; Tang PMK; Zhou Y; Cheng ASL; Yu J; Kang W; To KF
    Cells; 2019 Jun; 8(6):. PubMed ID: 31242658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of fibroblast growth factors and their receptors during multi-stage epidermal carcinogenesis in K14-HPV16 transgenic mice.
    Arbeit JM; Olson DC; Hanahan D
    Oncogene; 1996 Nov; 13(9):1847-57. PubMed ID: 8934530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.
    Hoshi T; Watanabe Miyano S; Watanabe H; Sonobe RMK; Seki Y; Ohta E; Nomoto K; Matsui J; Funahashi Y
    Biochem Biophys Res Commun; 2019 May; 513(1):1-7. PubMed ID: 30944079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications.
    Helsten T; Schwaederle M; Kurzrock R
    Cancer Metastasis Rev; 2015 Sep; 34(3):479-96. PubMed ID: 26224133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological Significance and Targeting of the FGFR Axis in Cancer.
    Chioni AM; Grose RP
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity.
    Jo JC; Choi EK; Shin JS; Moon JH; Hong SW; Lee HR; Kim SM; Jung SA; Lee DH; Jung SH; Lee SH; Kim JE; Kim KP; Hong YS; Suh YA; Jang SJ; Choi EK; Lee JS; Jin DH; Kim TW
    Mol Cancer Ther; 2015 Nov; 14(11):2613-22. PubMed ID: 26351320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.